CABA vs CBRE · $143.9M cap vs P/E 43, rev $35.77B
Cabaletta Bio Inc (CABA) versus CBRE Group Inc Class A (CBRE) — a side-by-side from cached financials, not a winner call.
Cabaletta Bio Inc (CABA) is a biotechnology company listed on US.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
CABA does not have a complete income-statement cache yet.
Latest reported CBRE revenue for 2024-12-31 was $35.77B. Net income was $1.04B. Revenue was up 12.0% from 2023-12-31 to 2024-12-31. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
CABA currently screens at market cap $143.9M. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Not investment advice. Open the CABA and CBRE stock pages for the full models.
Not investment advice.